Market LIVE
Published markets; coverage varies by country
Product profile · United States

XOFLUZA

 ·  Patent Litigation & Settlement History ↓

IngredientBALOXAVIR MARBOXIL
Application typeNDA
Application210854
Product001
Dosage formTABLET
RouteORAL
Strength20MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Approval date2018-10-24
Marketing statusDISCONTINUED
Status event—
ApplicantGENENTECH INC
Product source

Current GenericRadar decision

Year2023
SelectionDISQUALIFIED
ReviewFINAL
Anchor typeFDA_DISCONTINUATION
Anchor date—
Patent anchor2036-04-27
Exclusivity anchor2023-10-24
Protection date2039-10-09
First Final ANDA—
Status event—

FDA_MARKETING_DISCONTINUED; US:NDA:210854:001; exact Final ANDA not verified; not proof of generic absence

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
98158352030-06-14DP —NYU
English description not available.
———
98158352030-06-14ORANGE_BOOK —NYU
English description not available.
———
89277102031-05-05DP —NYU
English description not available.
———
89277102031-05-05ORANGE_BOOK —NYU
English description not available.
———
89874412032-10-24DS/DP —YNTRUE_DS
English description not available.
———
89874412032-10-24ORANGE_BOOK —YNTRUE_DS
English description not available.
———
103924062036-04-27DS —YNTRUE_DS
English description not available.
———
103924062036-04-27ORANGE_BOOK —YNTRUE_DS
English description not available.
———
106333972036-04-27U U-3000NYU
English description not available.
———
106333972036-04-27U U-2816NYU
English description not available.
———
106333972036-04-27ORANGE_BOOK U-2816,U-3000NYU
English description not available.
———
107598142037-08-09DS/DP —NNDP
English description not available.
———
107598142037-08-09ORANGE_BOOK —NNDP
English description not available.
———
113061062037-08-09U U-3000NNU
English description not available.
———
113061062037-08-09U U-2816NNU
English description not available.
———
113061062037-08-09ORANGE_BOOK U-2816,U-3000NNU
English description not available.
———
112611982038-09-25DP —NNOTHER
English description not available.
———
112611982038-09-25ORANGE_BOOK —NNOTHER
English description not available.
———
120644382039-10-09DP —NNDP
English description not available.
———
120644382039-10-09ORANGE_BOOK —NNDP
English description not available.
———

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
I-8112019-10-162022-10-16English description not available.NN—
NCE
Full coverage date: —
Source
NCE2018-10-242023-10-24English description not available.YY2023-10-24
NCE
Full coverage date: 2023-10-24
Source
M-1872024-12-192027-12-19English description not available.NN——Source
M-1872024-12-192027-12-19English description not available.NN—
NCE
Full coverage date: —
Source

2026-10-10 · CURRENT_SOURCE_RECORDS_FOUND · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
No generic approval facts are linked to this product.

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 0 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
No final-approval records are linked to this product.
Decision evidence (13)
TypeDateRoleBasisSource
PATENT2030-06-14HISTORICAL_CONTEXTEnglish description not available.Source
PATENT2031-05-05HISTORICAL_CONTEXTEnglish description not available.Source
PATENT2032-10-24HISTORICAL_CONTEXTEnglish description not available.Source
PATENT2036-04-27HISTORICAL_CONTEXTEnglish description not available.Source
PATENT2036-04-27HISTORICAL_CONTEXTEnglish description not available.Source
PATENT2037-08-09HISTORICAL_CONTEXTEnglish description not available.Source
PATENT2037-08-09HISTORICAL_CONTEXTEnglish description not available.Source
PATENT2038-09-25HISTORICAL_CONTEXTEnglish description not available.Source
PATENT2039-10-09HISTORICAL_CONTEXTEnglish description not available.Source
REGULATORY_EXCLUSIVITY—HISTORICAL_CONTEXTEnglish description not available.Source
REGULATORY_EXCLUSIVITY—HISTORICAL_CONTEXTEnglish description not available.Source
REGULATORY_EXCLUSIVITY—HISTORICAL_CONTEXTEnglish description not available.Source
REGULATORY_STATUS—TERMINAL_STATUSFDA_MARKETING_DISCONTINUED; US:NDA:210854:001; exact Final ANDA not verified; not proof of generic absenceSource
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.